At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 110 enrolled
Drug / intervention
LHA510 Ophthalmic Suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Vehicle-Controlled, First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Topically Delivered LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration
In Brief
A Phase 1 clinical trial evaluating LHA510 Ophthalmic Suspension and LHA510 Vehicle for Age-Related Macular Degeneration. Completed, enrolled 110 participants.
Detailed Summary
The purpose of this first-in-human study is to assess the local ocular and systemic safety and tolerability of LHA510 eye drops when administered at various concentrations and dosing frequencies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedMar 2014
Primary CompletionJun 2014
TodayJul 2026
First PostedMar 4, 2014
Enrollment StartFeb 1, 2014
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.3 years ago
Interventions
LHA510 Ophthalmic Suspensiondrug
Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
LHA510 Vehicledrug
Inactive ingredients used for masking purposes